Detection of mutations in the BCR/ABL fusion gene in patients with chronic myeloid leukemia - resistance to therapy

Chronic myeloid leukemia (CML) is one of the most frequent types of leukemia among adult patients. In over 80% of cases, the emergence of this disease is accompanied by the presence of t(9;22) translocation (Philadelphia chromosome) which causes the formation of BCR-ABL (p210) fusion transcript. This fusion transcript represents the target for specific therapy (GLEEVEC - imatinib mesylate). However, during the treatment of the CML, some patients can acquire resistance to GLEEVEC caused by the presence of mutations in BCR-ABL fusion transcript.

In the Laboratory for Molecular Biomedicine we offer a service for detection of resistance causing mutations in BCR-ABL fusion transcript by application of reverse-transcriptase PCR method, followed by direct sequencing. This method is recommended by the experts from European LeukemiaNet.

It is necessary to deliver 10 ml peripheral blood using 3.8% sodium citrate as anticoagulant in vol/vol ratio 9:1. The sample is required to be delivered fresh, without freezing, during the same day. The samples are accepted every day from 10 to 13h. It is possible to deliver the sample via post express service. The analysis is performed within 10 working days. The results and the bill are sent to the patient's home address, or can be collected personally at the Institute from 10 to 16h every day.

For payment instructions, please contact us.

 

CONTACT:

  • dr Nataša Tošić
  • dr Sonja Pavlović

Tel: +381 11 3976 445

Mob: +381 65 3976 445

Fax: +381 11 3975 808

e-mail: zmzg@sezampro.rs

Please publish modules in offcanvas position.